Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening

Drug combinatorial screening was used to identify effective combinations for mutant BRAF melanomas, including those resistant to vemurafenib, and mutant RAS melanomas that are resistant to many therapies.

http://cancerdiscovery.aacrjournals.org/content/early/2012/12/07/2159-8290.CD-12-0408.abstract